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Abstract
We describe a patient with conﬁrmed novel H1N1 (swine-like)
inﬂuenza A virus who had daily nasal swabs tested during oseltamivir
therapy. Nasal shedding remained positive for 2 days and became
negative on day 3. This report presents the ﬁrst available data on the
kinetics of shedding of this novel virus under antiviral therapy.
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Testing of nasal swab specimens is a validated diagnostic
method for inﬂuenza which is used with success for the diag-
nosis of the novel H1N1 (swine-like) inﬂuenza A virus [1,2].
However, a follow-up study of nasal shedding of this novel
virus under antiviral therapy is not available so far. We
describe here a patient with conﬁrmed novel H1N1 (swine-
like) inﬂuenza A who beneﬁted from daily swab examination
under oseltamivir therapy. The kinetics of nasal viral eradica-
tion and its impact on medical management are presented
and discussed.
Case report
A 37-year-old male French Caucasian patient was hospital-
ized at the Centre d’Infectiologie Necker-Pasteur, Paris, for
mild fever (38C), dyspnoea, cough and myalgia following a
trip to Yucatan, Mexico. He had no signiﬁcant past history,
or any tobacco, alcohol or drug exposure, and did not
receive any medication. Symptoms developed 2 days after he
returned from an 11-day trip to Cancun and Tulum, Mexico,
with his wife and two sons. The trip included a visit to a
Mayan village, where they had close contact with poultry.
The patient spent 3 h waiting for a connecting ﬂight at Mex-
ico International airport on his way back to Paris, France. He
did not recall any direct contact with swine or patients with
inﬂuenza. Physical examination revealed apyrexia, a normal
respiratory rate, and a mild conjunctival hyperaemia. Blood
oxygen saturation was 96%. Headache and myalgia were
noted, as well as mild shortness of breath at rest, but no
digestive or neurological disturbance. Lung examination ﬁnd-
ings were normal. A chest radiograph showed no abnormali-
ties. Laboratory test results were unremarkable. A
nasopharyngeal swab allowed the detection of inﬂuenza A
virus using RT-PCR targeting the M gene, albeit at a low
virus load. Seasonal H1N1 and H3N2 inﬂuenza strains were
not detected. The H1N1 (swine-like) inﬂuenza A virus was
detected upon random ampliﬁcation of the RNA using the
phi29 polymerase [3] and subsequent determination of the
sequences of the M gene by pyrosequencing as previously
described [4], but using the primers MR (biotin-
AGTAGAAACAAGGTAGTTTTTTACTC) and M2F (CAGA-
TGCAGCGATTCAAGTG) for ampliﬁcation and M2F for
sequencing. The nucleotide sequence (nucleotides 759–784)
was identical to that of A/California/4/2009(H1N1) (swine-
like) [2], and was shown to encode the S31N change known
to confer resistance to adamantanes.
Antiviral treatment with oseltamivir (75 mg/day) was
started on admission 48 h after the onset of symptoms.
The evolution was favourable, with complete disappearance
of symptoms within 2 days. Nasal swab samples were
obtained daily. Interestingly, they remained positive for
2 days, with comparable viral loads, and became negative
on the third day of treatment. The patient was then
discharged, having fully recovered from H1N1 (swine-like)
inﬂuenza A. No other case of inﬂuenza was detected
among familial contacts.
This patient with a virologically conﬁrmed diagnosis of
imported swine-like inﬂuenza presented with mild clinical
symptoms in the absence of comorbidity, a clinical picture
corresponding to one reported in the USA [2]. He bene-
ﬁted from antiviral therapy within 48 h after the onset of
symptoms, as recommended (http://www.cdc.gov/h1n1ﬂu/
recommendations.htm). Recently published data have
documented the susceptibility of available swine inﬂu-
enza isolates to neuraminidase inhibitors [2], but, to our
knowledge, we are the ﬁrst to report an evaluation of the
kinetics of nasal shedding of the H1N1 (swine-like)
inﬂuenza A virus under oseltamivir treatment. Nasal viral
shedding became negative 3 days after initiation of appro-
priate and early antiviral therapy. This duration appears to
be similar to that reported for cases of human seasonal
H3N2 inﬂuenza A or inﬂuenza B, with 73% of patients
whose nasal samples became negative by day 3, and 1–5%
of patients whose samples were still positive at day 5 [5].
In a recent meta-analysis of the efﬁcacy of registered
antivirals against seasonal inﬂuenza, viral nasal titres were
signiﬁcantly reduced by oseltamivir, which also improved
the status of patients with symptomatic inﬂuenza and
prevented lower respiratory tract complications [6].
Thus, treatment should also contribute to reducing trans-
mission. However, delayed viral clearance with shedding of
more than 10 days has been reported among immunocom-
promised patients, including lymphopenic patients and
patients who have undergone bone marrow transplantation
[7,8]. Prolonged shedding of an H1N1 inﬂuenza A virus may
also suggest resistance to neuraminidase inhibitors, as it has
been reported in up to 15% of cases during seasonal inﬂu-
enza [9].
This preliminary report regarding an immunocompetent
adult does not suggest that nasal viral shedding during
swine-like inﬂuenza occurring in humans differs from what is
currently reported during seasonal H1N1 inﬂuenza A, mean-
ing that isolation procedures can be stopped as early as at
the end of oseltamivir therapy, provided that respiratory
symptoms have disappeared. Larger studies are needed to
conﬁrm these data and to assess the potential acquisition of
resistance to neuraminidase inhibitors of this recently
emerged swine-like inﬂuenza virus, at least in patients with
persistent clinical symptoms.
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